Table 2.

Results from adult ABOi renal transplant programs using rituximab

Authors	Number of patients	Dose of rituximab	Follow‐up	Outcome
Sonnenday et al60	6	375 mg/m2, single dose	12 mo	Mean SCR. was 1.3 ± 0.1 mg/dL
				No episodes of AMR
				Stable allograft function
Genberg et al61	15	375 mg/m2, single dose	3 y	100% patient survival
				87% overall graft survival
				Acute rejection in 1 patient
Sivakumaran et al62	10	375 mg/m2, single dose	1 y	100% patient survival
				Mean SCr = 1.45 ± 1.04 mg/dL
				4 episodes of AMR
				2 incidents of DGF
Genberg et al63	43	375 mg/m2, single dose	4.5 y	93% overall patient survival
				91% graft survival
				9.3% incidence of AMR
Melexopoulou et al64	30	375 mg/m2, single dose	6 y	92% patient survival
				81% graft survival
				No CAMR
				13.3% ACR
Jha et al65	20	200 mg, single dose		90% patient survival
				95% graft survival
				15% AMR
Lee et al66	59	375 mg/m2, or 200 mg single dose	2 y	95.8% patient survival
				94.9% graft survival
				15.3% AMR
				1 graft loss
Kong et al67	79	53% patients mean 644 ± 226 mg/body47% patients 203 ± 14 mg/body	21 mo	99.2% patient survival
				97.5% graft survival
				14% patients had acute rejection
Rostaing et al68	12	375 mg/m2, two dose	19 mo	91.6% graft survival
				100% patient survival
				3 patient had CAMR
				58.3% showed nearly normal kidney biopsy
Ray et al69	45	200 mg/body single infusion	370 d	Mean SCr = 1.21 mg%
				97.78% graft survival
				97.78% patient survival

ACR, acute cellular rejection; AMR, antibody‐mediated rejection; CAMR, chronic antibody‐mediated rejection; DGF, delayed graft function; SCR, serum creatinine.